Welcome to our dedicated page for Assembly Biosciences news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences stock.
Assembly Biosciences, Inc. reports developments for a clinical-stage biotechnology business focused on small-molecule therapeutics for serious viral diseases. Its recurring updates center on investigational antiviral candidates for herpes simplex virus, hepatitis delta virus and hepatitis B virus, including helicase-primase inhibitors ABI-5366 and ABI-1179, the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334.
Company news also covers clinical data presentations, financial results, research and collaboration revenue, the Gilead collaboration and licensing activity, and equity financing transactions that support pipeline development.
Assembly Biosciences (ASMB)/b) will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.A live webcast of the senior management presentation will be available in the Events and Presentations section of Assembly Bio’s website, with a replay accessible after the event. Registration for both the live webcast and replay is available at the company’s investor relations events page.
Assembly Biosciences (ASMB) has exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor program for recurrent genital herpes under its collaboration with Gilead Sciences.
Gilead retains sole responsibility for clinical development and commercialization of the HSV HPI program, which includes GS-1179 and GS-5366. Assembly Bio is eligible for up to $280 million in regulatory and commercial milestones plus tiered royalties on net sales outside the U.S. ranging from high single-digits to low teens. If the U.S. profit share is ended under either party’s opt-out or conversion rights, economics could shift to up to $330 million in milestones with similar royalty tiers.
GS-1179 is expected to enter a Phase 2 trial in recurrent genital herpes by the end of 2026. Including a $75 million continuation payment due from Gilead in Q4 2026, Assembly Bio projects its cash runway into 2029.
Assembly Biosciences (Nasdaq: ASMB) reported second quarter 2026 results and pipeline updates, highlighting expansion of ABI-6250 into cholestatic liver diseases, including PBC and PSC, with a Phase 2 study expected to start in Q1 2027 and another Phase 2 in chronic HDV targeted by year-end 2026.
The company completed a $115 million gross financing and reported cash, cash equivalents and marketable securities of $320.4 million at June 30, 2026, with cash runway projected into 2029 including a planned $75 million Gilead extension payment in Q4 2026. Q2 2026 collaboration revenue from Gilead rose to $13.4 million from $9.6 million, R&D expenses declined to $14.9 million from $16.1 million, and net loss narrowed to $3.9 million (–$0.20 per share) from $10.2 million (–$1.33) a year earlier. Gilead selected GS-1179 to advance in the HSV HPI program, with Phase 2 initiation in recurrent genital herpes expected by year-end 2026.
Assembly Biosciences (Nasdaq: ASMB) announced senior management will participate in fireside chats at two upcoming investor conferences.
The company will present at the Jefferies 2026 Global Healthcare Conference on June 3, 2026 at 4:20 p.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 8:40 a.m. ET. Live webcasts and replays will be available on Assembly Bio’s investor relations website.
Assembly Biosciences (Nasdaq: ASMB) closed its underwritten registered offering of 3,924,624 common shares at $26.50 per share, including full exercise of underwriters’ option for 566,040 additional shares.
The company also sold pre-funded warrants for 415,000 shares, raising approximately $115 million in gross proceeds to fund clinical pipeline development and general corporate purposes.
Assembly Biosciences (Nasdaq: ASMB) priced a registered underwritten offering of approximately $100 million in common stock and pre-funded warrants. The deal covers 3,358,602 shares at $26.50 each and 415,000 pre-funded warrants at $26.499, plus a 30-day option for 566,040 additional shares.
All securities are offered by the company, with closing expected around May 26, 2026. Proceeds are planned to fund clinical development of pipeline candidates and general corporate purposes. Participants include new and existing healthcare-focused investors such as Gilead Sciences and several specialist funds.
Assembly Biosciences (Nasdaq: ASMB) plans to expand development of ABI-6250, an oral NTCP inhibitor for chronic HDV, into cholestatic liver diseases PBC and PSC. A Phase 2 HDV trial is planned for Q4 2026 and a Phase 2 basket study in PBC/PSC for Q1 2027, pending regulatory input.
According to Assembly Bio, Phase 1a data showed target engagement with dose‑dependent increases in plasma bile acids, and chronic toxicology studies support longer-term dosing. ABI-6250 remains investigational, with safety and efficacy not yet established.
Assembly Biosciences (Nasdaq: ASMB) will present topline Phase 1a data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, at the EASL Congress 2026 in Barcelona on May 27, 2026.
The randomized, blinded study evaluates safety, pharmacokinetics and pharmacodynamic activity in healthy participants.
Assembly Biosciences (Nasdaq: ASMB) announced that chief medical officer Anuj Gaggar, MD, PhD, will present at the BofA Securities 2026 Global Health Care Conference at 4:35 p.m. PT on May 13, 2026. A live webcast and replay will be available via the company’s investor relations website.
Assembly Biosciences (Nasdaq: ASMB) reported Q1 2026 results and program updates on May 7, 2026. Key development milestones include completed Phase 1b follow-up for ABI-5366 and ABI-1179, completed chronic toxicology for ABI-6250, and an expected Phase 2 start for ABI-6250 in Q4 2026.
Financials: $226.6M cash and marketable securities at March 31, 2026, projected runway into 2028; collaborative revenue with Gilead was $8.2M in Q1; net loss attributable to common stockholders was $9.1M (loss per share $0.54).